Back to top

Analyst Blog

Osiris Therapeutics Inc.’s (OSIR - Analyst Report) shares, which were up 25.1% immediately after the company reported third quarter results, were down 9.3% in the following trading session. Overall, shares are up 20.9% since the release of third quarter results. Osiris’ third quarter results were better-than-expected with the company reporting break-even earnings, well above the Zacks Consensus Estimate of a loss of 9 cents and the year-ago loss of a penny per share.

Revenues for the quarter came in at $6.9 million, in line with the Zacks Consensus Estimate and well above the year-ago quarter revenues of $2.2 million.

Research and development (R&D) expenses declined 25.3% from the year-ago period to $0.9 million. The company intends to study Grafix for the treatment of venous leg ulcers.

Selling, general and administrative expenses increased to $4 million from $0.7 million in the year-ago period due to higher commercial activities.

Meanwhile, in early Oct 2013, Osiris sold its culture-expanded mesenchymal stem cell (ceMSC) business including Prochymal (for up to $100 million) to a wholly-owned subsidiary of Mesoblast Limited. Osiris will be entitled to royalty payments as well.

Osiris also stated that the FDA does not require the company to file a biologic license application (BLA) for Grafix to remain on the market. However, the company intends to submit a BLA for enhanced label claims in the next 12-18 months.

Osiris intends to continue investing in its sales force and expects to have about 50 sales reps promoting Grafix within the next 6 months.

Osiris is a Zacks Rank #4 (Sell) stock. At present, companies like Actelion Ltd. (ALIOF), AMAG Pharmaceuticals, Inc. (AMAG - Snapshot Report) and Isis Pharmaceuticals, Inc. (ISIS - Analyst Report) look well-positioned with all three carrying a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
GTT COMMUNI… GTT 11.65 +4.11%
ALLERGAN IN… AGN 161.82 +3.99%
CLAYTON WIL… CWEI 117.06 +3.73%
GREENBRIER… GBX 69.63 +2.37%
RF MICRO DE… RFMD 12.02 +2.04%